Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

Arthritis Research & Therapy
Won ParkJürgen Braun

Abstract

CT-P13 (Remsima®, Inflectra®) is a biosimilar of the infliximab reference product (RP; Remicade®) and is approved in Europe and elsewhere, mostly for the same indications as RP. The aim of this study was to compare the 54-week efficacy, immunogenicity, pharmacokinetics (PK) and safety of CT-P13 with RP in patients with ankylosing spondylitis (AS), with a focus on patient-reported outcomes (PROs). This was a multinational, double-blind, parallel-group study in patients with active AS. Participants were randomized (1:1) to receive CT-P13 (5 mg/kg) or RP (5 mg/kg) at weeks 0, 2, 6 and then every 8 weeks up to week 54. To assess responses, standardized assessment tools were used with an intention-to-treat analysis of observed data. Anti-drug antibodies (ADAs), PK parameters, and safety outcomes were also assessed. Of 250 randomized patients (n = 125 per group), 210 (84.0 %) completed 54 weeks of treatment, with similar completion rates between groups. At week 54, Assessment of Spondylo Arthritis international Society (ASAS)20 response, ASAS40 response and ASAS partial remission were comparable between treatment groups. Changes from baseline in PROs such as mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; CT-P13 -3.1...Continue Reading

References

Nov 30, 2000·The New England Journal of Medicine·P E LipskyUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
Feb 14, 2003·The New England Journal of Medicine·Filip BaertPaul Rutgeerts
Nov 6, 2004·Arthritis and Rheumatism·E William St ClairUNKNOWN Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Grou
Feb 5, 2005·Arthritis and Rheumatism·Désirée van der HeijdeUNKNOWN Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group
Jan 1, 2008·Arthritis and Rheumatism·Maxime BrebanUNKNOWN French Ankylosing Spondylitis Infliximab Network
May 5, 2011·Annals of the Rheumatic Diseases·J BraunD van der Heijde
May 5, 2011·Annals of the Rheumatic Diseases·Désirée van der HeijdeUNKNOWN Assessment of SpondyloArthritis international Society
May 9, 2012·Annals of the Rheumatic Diseases·Chamaida PlasenciaAlejandro Balsa
Mar 8, 2013·Annals of the Rheumatic Diseases·Polina PutrikUNKNOWN Working Group ‘Equity in access to treatment of rheumatoid arthritis in Europe’
Dec 18, 2014·MAbs·Soon Kwan JungShin Jae Chang

❮ Previous
Next ❯

Citations

Mar 5, 2016·Drugs·Filipe AraújoJoão Eurico Fonseca
Sep 27, 2016·Expert Opinion on Biological Therapy·Freddy FaccinTeotonio Albuquerque
Oct 25, 2016·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Shomron Ben-HorinPeter Laszlo Lakatos
Oct 1, 2016·Expert Review of Clinical Immunology·Daniela PuglieseAlessandro Armuzzi
Jan 11, 2017·Expert Opinion on Drug Safety·J Braun, J Kay
Jan 18, 2017·Expert Review of Clinical Pharmacology·Sean McConachiePramodini B Kale-Pradhan
May 13, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Walter ReinischDae Hyun Yoo
Mar 18, 2017·Current Opinion in Rheumatology·Stanley Cohen, Jonathan Kay
Jun 3, 2017·Expert Review of Clinical Immunology·Dae Hyun Yoo
Jun 29, 2017·Journal of Pediatric Gastroenterology and Nutrition·Lissy de Ridder, Harland Winter
Feb 25, 2018·Expert Opinion on Emerging Drugs·Judith Rademacher, Denis Poddubnyy
Nov 28, 2017·Journal of Comparative Effectiveness Research·Dae Hyun Yoo
Apr 30, 2017·Annals of the Rheumatic Diseases·Karin A van SchieTheo Rispens
Jun 13, 2018·Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva·María Fernanda Guerra VelozFederico Argüelles Arias
Oct 20, 2018·International Journal of Rheumatic Diseases·Prasan Deep RathLyndon Llamado
Sep 1, 2018·Journal of Pediatric Gastroenterology and Nutrition·Lissy de RidderUNKNOWN Paediatric IBD Porto group of ESPGHAN
Feb 1, 2018·Zeitschrift für Rheumatologie·J BraunT Dörner
Feb 16, 2019·International Journal of Rheumatic Diseases·Zohra LayeghGertjan Wolbink
Jul 31, 2018·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Valderilio Feijó AzevedoHeather E Jones
May 15, 2018·Current Medicinal Chemistry·Silvio Danese, Gionata Fiorino
Oct 17, 2019·Cadernos de saúde pública·Paula Teixeira Pinto Ferreira NetoMarco Antonio Vargas
Aug 14, 2019·Expert Opinion on Biological Therapy·Ahmad Albshesh, Shomron Ben-Horin
Sep 14, 2017·European Journal of Gastroenterology & Hepatology·Federico Argüelles-AriasManuel Romero Gómez
Mar 3, 2020·Expert Opinion on Drug Safety·Kelly A ReynoldsJashin J Wu
Sep 4, 2017·Annals of the Rheumatic Diseases·Jonathan KayUNKNOWN Task Force on the Use of Biosimilars to Treat Rheumatological Diseases
Jun 28, 2018·Annals of the Rheumatic Diseases·Karin A van SchieTheo Rispens
Sep 1, 2017·Expert Opinion on Drug Safety·Marta Pérez-De-LisManuel Ramos-Casals
May 11, 2016·Pharmacological Reports : PR·Marcin WłodarczykAleksandra Sobolewska-Włodarczyk
Oct 2, 2020·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Gennadiy A KatsevmanSanjay Bhatia
Apr 5, 2017·World Journal of Gastroenterology : WJG·Michael K ZhengGary C Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray
ESR

Clinical Trials Mentioned

NCT01220518
NCT02148640

Software Mentioned

SAS
PLANETRA
PLANETAS
NOR
SWITCH

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.